Pasithea Therapeutics (KTTA) Profit After Tax (2021 - 2024)
Pasithea Therapeutics (KTTA) has disclosed Profit After Tax for 4 consecutive years, with -$3.2 million as the latest value for Q4 2024.
- Quarterly Profit After Tax rose 36.84% to -$3.2 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was -$13.9 million through Dec 2024, up 12.8% year-over-year, with the annual reading at -$20.4 million for FY2025, 46.91% down from the prior year.
- Profit After Tax hit -$3.2 million in Q4 2024 for Pasithea Therapeutics, down from -$3.0 million in the prior quarter.
- In the past five years, Profit After Tax ranged from a high of $630143.0 in Q4 2021 to a low of -$5.1 million in Q4 2022.
- Historically, Profit After Tax has averaged -$2.9 million across 4 years, with a median of -$3.4 million in 2023.
- Biggest five-year swings in Profit After Tax: crashed 912.15% in 2022 and later skyrocketed 36.84% in 2024.
- Year by year, Profit After Tax stood at $630143.0 in 2021, then plummeted by 912.15% to -$5.1 million in 2022, then increased by 1.69% to -$5.0 million in 2023, then surged by 36.84% to -$3.2 million in 2024.
- Business Quant data shows Profit After Tax for KTTA at -$3.2 million in Q4 2024, -$3.0 million in Q3 2024, and -$3.9 million in Q2 2024.